Development Of New Anti-Diabetic Drugs For Type 2 Diabetes
The global metabolic disorder drugs market was valued around $87 billion in 2017. North America was the largest region in the metabolic disorder drugs market in 2017, accounting 53% market share.
(EMAILWIRE.COM, November 16, 2018 ) Drug manufacturers are developing various anti-diabetic drugs for type-2 diabetes treatment. Type 2 diabetes is a noninsulin-dependent diabetes that affects sugar (glucose) metabolism of the patient by either resisting or restricting the effects of insulin. In July 2017, researchers at the University of California found that Amlexanox, a repurposed asthma drug with anti-inflammatory and anti-allergic properties, can improve blood sugar levels in type 2 diabetic patients. Similarly, in April 2017, scientists from the Central Drug Research Institute (CDRI) in India had found that chalcone, a plant-derived substance, can be used to produce an anti-diabetic drug that can improve insulin sensitivity and reduce blood glucose levels in patients with type-2 diabetes.
THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL METABOLIC DISORDER DRUGS MARKET TO GROW TO $125 BILLION BY 2021
North America was the largest region in the metabolic disorder drugs market, accounting for more than half of the market share. This can be attributed to high prevalence of metabolic syndrome (combination of metabolic diseases including type-2 diabetes) in the USA.
Order the report at https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report-2018
According to The Business Research Company’s Consultant, Nitin Gianchandani, administration (FDA) has approved various enzyme replacement therapies for the treatment of metabolic disorders. Enzyme replacement therapy is used for treatment of rare genetic disorders through purified human, animal or recombinant enzymes. In December 2015, the FDA approved an enzyme replacement therapy Kanuma that can be used to treat adult and pediatric patients suffering from lysosomal acid lipase deficiency, a metabolic disorder that causes problems with the breakdown and use of fats and cholesterol in the body. Similarly, in October 2015, FDA had announced the approval of Strensiq, a drug that can be used for the treatment of perinatal, infantile and juvenile-onset hypophosphatasia, which is a metabolic disorder affecting multiple body systems.
Download a sample of the report at https://www.thebusinessresearchcompany.com/sample.aspx?id=277&type=smp
Sanofi S.A. was the largest company in the metabolic disorder drugs market, with revenues of $11.23 billion in 2016. Sanofi’s growth strategy is to develop small molecule drugs for the treatment of major metabolic disorders. In January 2016, the company entered into a partnership with drug discovery company Jubilant Biosys Limited to discover and develop small molecule inhibitors targeting multiple metabolic disorders, including diabetes. Similarly, in May 2017, Sanofi had entered into an agreement with pharmaceutical company Exscientia to discover small-molecule drugs against metabolic diseases.
The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism. Some of the major drugs used in the treatment of metabolic diseases are Insulin, Methimazole, and Calcimimetics. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.
Metabolic Disorder Drugs Global Market Report 2018 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office, the price is $6000 and $8000 if you wish to use across a multinational company.
About The Business Research Company
Visit TheBusinessResearchCompany.com, mail info@tbrc.info or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.
The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.
It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.
The Business Research Company's management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world's largest organizations
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company
THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL METABOLIC DISORDER DRUGS MARKET TO GROW TO $125 BILLION BY 2021
North America was the largest region in the metabolic disorder drugs market, accounting for more than half of the market share. This can be attributed to high prevalence of metabolic syndrome (combination of metabolic diseases including type-2 diabetes) in the USA.
Order the report at https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report-2018
According to The Business Research Company’s Consultant, Nitin Gianchandani, administration (FDA) has approved various enzyme replacement therapies for the treatment of metabolic disorders. Enzyme replacement therapy is used for treatment of rare genetic disorders through purified human, animal or recombinant enzymes. In December 2015, the FDA approved an enzyme replacement therapy Kanuma that can be used to treat adult and pediatric patients suffering from lysosomal acid lipase deficiency, a metabolic disorder that causes problems with the breakdown and use of fats and cholesterol in the body. Similarly, in October 2015, FDA had announced the approval of Strensiq, a drug that can be used for the treatment of perinatal, infantile and juvenile-onset hypophosphatasia, which is a metabolic disorder affecting multiple body systems.
Download a sample of the report at https://www.thebusinessresearchcompany.com/sample.aspx?id=277&type=smp
Sanofi S.A. was the largest company in the metabolic disorder drugs market, with revenues of $11.23 billion in 2016. Sanofi’s growth strategy is to develop small molecule drugs for the treatment of major metabolic disorders. In January 2016, the company entered into a partnership with drug discovery company Jubilant Biosys Limited to discover and develop small molecule inhibitors targeting multiple metabolic disorders, including diabetes. Similarly, in May 2017, Sanofi had entered into an agreement with pharmaceutical company Exscientia to discover small-molecule drugs against metabolic diseases.
The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism. Some of the major drugs used in the treatment of metabolic diseases are Insulin, Methimazole, and Calcimimetics. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.
Metabolic Disorder Drugs Global Market Report 2018 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office, the price is $6000 and $8000 if you wish to use across a multinational company.
About The Business Research Company
Visit TheBusinessResearchCompany.com, mail info@tbrc.info or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.
The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.
It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.
The Business Research Company's management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world's largest organizations
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company
Contact Information:
The Business Research Company
Marketing TBRC
Tel: +91 8897263534
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
The Business Research Company
Marketing TBRC
Tel: +91 8897263534
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results